Oral caffeine to reduce pain during acute migraine attacks
Official title: Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial
Run by Ain Shams University · NCT07022496 · Data updated 2026-11-12
This test will see if a single 200 mg oral caffeine tablet taken during an acute migraine can reduce pain for adults with episodic or chronic migraine with or without aura.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | April 26, 2023 |
| Main results expected | July 2025 |
| Study ends | August 2025 |
| Registry record updated | June 15, 2025 |
| Trial ID | NCT07022496 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with episodic or chronic migraine, with or without aura, diagnosed according to ICHD-3 who can attend the Ain Shams University outpatient clinic are eligible.
✕Probably not a fit
Patients with cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, certain psychiatric disorders, pregnancy or breastfeeding, renal or hepatic failure, sleep disorders, substance abuse, or those with secondary headache causes are excluded and unlikely to be appropriate or benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults diagnosed with migraine by ICHD-3 criteria are given a 200 mg caffeine tablet extracted from green tea during an acute migraine attack and pain severity is measured using a visual analogue scale (VAS) before and after treatment. The protocol allows common acute migraine medications such as triptans, NSAIDs, or paracetamol as listed interventions and records responses alongside caffeine use. The study is conducted in the headache and neurology outpatient clinics at Ain Shams University and targets real-world clinic patients. The main outcome is change in VAS pain score following the caffeine dose.
Why it matters
Potential benefit: If effective, a single 200 mg caffeine tablet could offer a simple, low-cost option to reduce pain during acute migraine attacks.
How similar studies have gone: Prior research has shown that caffeine can enhance analgesic effects when combined with pain relievers, but using a standalone 200 mg caffeine tablet from green tea to abort acute migraine is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study. Exclusion Criteria: Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded
Where it's running
-
Ainshams university
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Nourhan Nader Elguindy, Masters degree
- Email: nourhanelguindy@gmail.com
- Phone: 00201128215952
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gepants for Acute Migraine in the Emergency Department
This study tests whether rimegepant or zavegepant given in the ED can relieve an acute migraine for adults.
-
Comparing biodegradable versus metal PFO occluders for people with migraine
We will test whether a biodegradable heart occluder works better than a metal occluder to reduce migraine symptoms in adults with a patent foramen ovale.
-
Yoga-based Movements for Primary Headaches (YOURHEAD)
A yoga-based movement program is being tested to see if it can help reduce headaches and improve quality of life for adults with migraine and/or cluster headaches.
-
Neuropsychological and cognitive profile in adults with migraine
This project will test how thinking skills and psychological factors (like anxiety, depression, worry, and coping) relate to migraine in adults who have had migraine for at least one year.
-
Comparing EEG indicators to assess mindfulness therapy for migraine relief
This study is testing if mindfulness therapy can help people with frequent migraines feel better by looking at brain activity and using wearable devices to track progress at home.
-
Aerobic exercise to improve sensory, muscle, and psychosocial symptoms in women with migraine
This trial will test whether supervised aerobic exercise plus one pain neuroscience education session helps women aged 18–48 with migraine reduce disability and improve sensory, musculoskeletal, and psychosocial symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.